

Borja Hernández-Breijo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3655141/publications.pdf>

Version: 2024-02-01

62
papers

224
citations

1040056

9
h-index

1058476

14
g-index

64
all docs

64
docs citations

64
times ranked

412
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 65-73.	0.9	24
2	Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity. <i>Biomedicines</i> , 2022, 10, 727.	3.2	4
3	Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitors. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	2
4	Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. <i>RMD Open</i> , 2022, 8, e002216.	3.8	10
5	POS0623...CYTOKINE PRODUCTION BY BLOOD LYMPHOCYTES DEFINES A PROFILE ASSOCIATED WITH NON-REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF INHIBITORS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 549.2-550.	0.9	0
6	POS0617...ANTI INFlixIMAB ANTIBODIES DETECTED BY A DRUG TOLERANT ASSAY ARE FREQUENT BUT, IN MANY CASES, WITHOUT RELEVANT CLINICAL SIGNIFICANCE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 546.1-546.	0.9	0
7	Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-8.	1.1	0
8	Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 692557.	2.6	3
9	Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2021, 8, 683990.	2.6	1
10	BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors. <i>Scientific Reports</i> , 2021, 11, 11632.	3.3	5
11	Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, E1-E2.	3.4	0
12	Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. <i>Scientific Reports</i> , 2020, 10, 17099.	3.3	1
13	Dendritic Nanotheranostic for the Delivery of Infliximab: A Potential Carrier in Rheumatoid Arthritis Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9101.	4.1	6
14	Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2020, 11, 1913.	4.8	5
15	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 588-596.	1.6	6
16	Extracellular allograft inflammatory factor-1 (AIF-1) potentiates Th1 cell differentiation and inhibits Treg response in human peripheral blood mononuclear cells from normal subjects. <i>Human Immunology</i> , 2020, 81, 91-100.	2.4	2
17	FRI0582...GM-CSF PRODUCED BY CD4+ T CELLS AS A MARKER OF CLINICAL REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF INHIBITORS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 895.2-895.	0.9	0
18	SAT0084...SERUM ADIPOKINES PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF-INHIBITORS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 976.2-976.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2019, 18, 102372.	5.8	14
20	Low serum calprotectin levels correlate with the presence of biological drugs after the first year of treatment in patients with rheumatoid arthritis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2019, 79, 538-540.	1.2	1
21	Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986784.	3.2	1
22	P816 Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S529-S531.	1.3	0
23	Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 66.	3.5	10
24	AB0409...B CELLS PROFILE AS A BIOMARKER FOR EARLY IDENTIFICATION OF OPTIMAL RESPONDERS TO TNF INHIBITORS IN RHEUMATOID ARTHRITIS. , 2019, , .		0
25	FRI0095...CHANGES IN B CELL PROFILE AS INDICATOR OF CLINICAL REMISSION TO TNF INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
26	FRI0399...INFLIXIMAB TROUGH LEVELS AND DISEASE ACTIVITY PREDICT EARLY CLINICAL RESPONSE IN PATIENTS WITH AXIAL SPONDYLOARHRITIS. , 2019, , .		2
27	148...Antimalarial agents and other immunosuppressants influence BAFF levels in opposite directions in patients with systemic lupus erythematosus. , 2019, , .		0
28	FRI0198...ANTIMALARIAL AGENTS DIMINISH WHILE METHOTREXATE, AZATHIOPRINE AND MYCOPHENOLIC ACID INCREASE BAFF LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
29	The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. <i>Clinical Rheumatology</i> , 2019, 38, 949-954.	2.2	13
30	Differential blood cellular profile in patients with moderate-to-severe psoriasis treated with classical systemic therapies: a step forward in personalized medicine. <i>British Journal of Dermatology</i> , 2018, 179, 765-766.	1.5	0
31	AB0201...Association between baseline calprotectin serum levels and response to biological therapy in patients with rheumatoid arthritis. , 2018, , .		0
32	AB0418...The effect of concomitant methotrexate on serum tnf inhibitors levels and clinical response in patients with rheumatoid arthritis is dose dependent and greater than other dmards. , 2018, , .		0
33	AB0916...Efficacy and predictive factors of clinical response to tnf inhibitors in patients with axial and peripheral psoriatic arthritis. , 2018, , .		0
34	FRI0186...Concomitant csdmards influence clinical response to tnf inhibitors only in overweight patients with axial spondyloarthritis. , 2018, , .		0
35	FRI0102...Reduction of antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with previous failure to infliximab or adalimumab. , 2018, , .		0
36	SAT0141...Optimal circulating adalimumab levels range associated with good clinical response in rheumatoid arthritis patients. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
37	Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease. <i>Biomarkers</i> , 2017, 22, 133-144.	1.9	21
38	AB0375...The effect of concomitant use of methotrexate on the clinical activity in patients with rheumatoid arthritis under ANTI-TNFTHERAPY. , 2017, , .		0
39	FRIO194...Use of gloresponsetm NF- β -RE-LUC2P HEK293 cells to monitor drug and anti-drug antibody levels in serum. , 2017, , .		0
40	THU0661...Clinical relevance of detecting anti-adalimumab antibodies with a drug-tolerant assay. , 2017, , .		0
41	Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. <i>Biochemical Pharmacology</i> , 2016, 122, 33-41.	4.4	12
42	Su1199 Allograft Inflammatory Factor-1 (AIF-1) Stimulates Th1 Differentiation of Human T-Cells and Protects Them From Apoptosis. <i>Gastroenterology</i> , 2015, 148, S-435.	1.3	0
43	Tu1291 Infliximab Serum Levels Do Not Predict Remission After the Induction Phase in Crohn's Disease Patients. <i>Gastroenterology</i> , 2015, 148, S-849.	1.3	2
44	Mo1713 Binding of Infliximab to Human Serum Exosomes. <i>Gastroenterology</i> , 2015, 148, S-692.	1.3	0
45	Tu1292 Quantification of the Concentration of Antibodies Against Infliximab (IFX) in Human Serum Using a Pure Antibody As Calibrator. <i>Gastroenterology</i> , 2015, 148, S-850.	1.3	1
46	538 Correlation Between Adalimumab Serum Levels and Remission After the Induction Phase in Crohn's Disease Patients. <i>Gastroenterology</i> , 2015, 148, S-107-S-108.	1.3	4
47	Sa1919 Regulation of G1/S Checkpoint by Insulin Receptor Substrate-4 in Colon Cancer Cells and Its Possible Involvement in Colorectal Cancer. <i>Gastroenterology</i> , 2015, 148, S-354-S-355.	1.3	0
48	Tu1293 Soluble TNF Serum Levels During the Induction Phase in Crohn's Disease Patients With Anti-TNF Treatment. <i>Gastroenterology</i> , 2015, 148, S-850.	1.3	0
49	Effect of Infliximab in oxidised serum albumin levels during experimental colitis. <i>Biomarkers</i> , 2014, 19, 693-701.	1.9	3
50	Tu1705 Role of Allograft Inflammatory Factor 1 (AIF-1) in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2014, 146, S-822.	1.3	0
51	Tu1647 Effect of Infliximab Treatment on an Ulcerative Colitis Experimental Model in Rat. <i>Gastroenterology</i> , 2013, 144, S-814.	1.3	0
52	Azathioprine desensitizes liver cancer cells to insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1. <i>Toxicology and Applied Pharmacology</i> , 2013, 272, 568-578.	2.8	12
53	P080 Effect of insulin like growth factor-1 on experimental colitis. <i>Journal of Crohn's and Colitis</i> , 2013, 7, S41.	1.3	0
54	Is the Autophagy Induced by Thiopurines Beneficial or Deleterious?. <i>Current Drug Metabolism</i> , 2012, 13, 1267-1276.	1.2	11

#	ARTICLE	IF	CITATIONS
55	Mo2002 Desensitization of the IGF-I Receptor Signal Transduction in Rat Colon With Experimental Colitis. <i>Gastroenterology</i> , 2012, 142, S-717-S-718.	1.3	0
56	Su1211 The Autophagy Produced by Azathioprine in HEPG2 Cells Leads to Apoptotic Cell Death Due to Inhibition With Bafilomycin A1. <i>Gastroenterology</i> , 2012, 142, S-452.	1.3	0
57	Su1212 Azathioprine Produces Autophagy in Hepatoblastoma Cells by Desensitization to Insulin-Like Growth Factor 1 (IGF-1). <i>Gastroenterology</i> , 2012, 142, S-452.	1.3	0
58	493 AZATHIOPRINE PRODUCES AUTOPHAGY THROUGH ERK/MTOR/P70S6K PATHWAY IN HEPG2 CELLS. <i>Journal of Hepatology</i> , 2011, 54, S202.	3.7	0
59	Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma. <i>World Journal of Gastroenterology</i> , 2011, 17, 3899.	3.3	30
60	RNAi-mediated silencing of insulin receptor substrate-4 enhances actinomycin D- and tumor necrosis factor- α -induced cell death in hepatocarcinoma cancer cell lines. <i>Journal of Cellular Biochemistry</i> , 2009, 108, 1292-1301.	2.6	18
61	510 INSULIN RECEPTOR SUBSTRATE-4 INHIBITS AKT/PKB ACTIVITY FORMING A TERNARY COMPLEX WITH SHIP AND EGFR. EFFECT ON HEPG2 CANCER CELL MOTILITY. <i>Journal of Hepatology</i> , 2009, 50, S190.	3.7	0
62	710 AZATHIOPRINE PRODUCES OXIDIZATION OF 53 KDA AND 67 KDA PROTEINS AND INDUCES MITOCHONDRIAL DEPENDENT APOPTOSIS IN GSH DEPLETED HEPG2 CELLS. <i>Journal of Hepatology</i> , 2009, 50, S260.	3.7	0